Skip to main content

Cord Blood-derived Expanded Allogeneic Natural Killer Cells

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

  • RegistryNCT04991870
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Gliosarcoma
  • SponsorM.D. Anderson Cancer Center
How Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM worksNCT049918701 min

What the film says

Read the transcript

Recurrent glioblastoma resists nearly everything, partly because it bathes itself in TGF-beta, which puts immune cells to sleep, and because patients' steroids quiet them further.

The idea: natural killer cells edited so that neither signal can reach them, delivered straight into the tumor.

At MD Anderson, natural killer cells from donated umbilical cord blood are expanded and gene-edited to remove two receptors: the TGF-beta receptor, and the receptor for glucocorticoid steroids. They are then injected through a small reservoir under the scalp directly into the tumor, every four weeks, up to eight. In some patients, a dose comes before planned surgery, so the removed tissue shows whether the cells arrived and survived.

Shiao-Pei Weathers leads it, from age twelve. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04991870

    Cord blood-derived, expanded, allogeneic NK; TGF-βR2 and NR3C1 (glucocorticoid receptor) deleted; Intratumoral via Ommaya every four weeks, up to 8 doses (Group 1); Group 2: dose two weeks before resection; tissue analyzed for NK persistence; Ages ≥12; Shiao-Pei Weathers; MD Anderson

The drug

What is being tested.

Given CB-NK-TGF-betaR2-/NR3C1- intratumorally

PRIMARY OBJECTIVES: * To determine the safety and tolerability of intratumoral injection of escalating doses of allogeneic CB-NK-TGF-£]R2-/NR3C1- in patients with recurrent grade 4 astrocytoma, * To determine the maximum tolerated dose (MTD) and the occurrence of dose limiting toxicities (DLTs) (Group 1) of CB-NK-TGF-£]R2-/NR3C1- administered via IT injection in patients with recurrent grade 4 astrocytoma * To evaluate the immunological phenotype and anti-tumor function of NK cells in resected tumor tissue after treatment with CB-NK-TGF-âR2-/NR3C1- in the surgical expansion group (Group 2).

Persistency of the NK cells in the tissue will be assessed by flow cytometry. Tissue cells will be stained with anti human CD45, anti human CD56 and anti HLA molecule expressed by the cord blood donor infused in the patient. NK cells from the tissue may be isolated using magnetic bead selection (anti-HLA specific from cord blood donor labeled with PE and them use a anti PE magnetics bead selection).

The study

How the trial runs.

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Signed and dated informed consent.
  • Male or female participants aged ≥ 12 years on the day of signing informed consent.
  • Has histologically confirmed supratentorial World Health Organization grade 4 recurrent astrocytoma to include recurrent IDH WT glioblastoma or gliosarcoma and recurrent IDHmutant grade 4 astrocytoma, and recurrent gliosarcoma with any prior number of recurrences, and who have received prior radiation and temozolomide therapy. Participants will be eligible if the original histology was lower-grade glioma grade 2 or 3 and a subsequent histological diagnosis of recurrent glioblastoma or IDH-mutant grade 4 astrocytoma is made.
  • Karnofsky Performance Score (KPS) of >70 at trial entry. Lansky >70 at trial entry for patients less than 16.
  • Must be at least 12 weeks from receiving conformal radiation, unless RANO criteria for early progression are met.
  • A baseline brain MRI with Advance Brain Tumor Imaging (ABTI) must be obtained no more than 30 days prior to study registration

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.